18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer

被引:18
|
作者
Salem, Kelley [1 ]
Kumar, Manoj [1 ]
Powers, Ginny L. [1 ,5 ]
Jeffery, Justin J. [2 ]
Yan, Yongjun [1 ,3 ]
Mahajan, Aparna M. [4 ]
Fowler, Amy M. [1 ,2 ,3 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, 600 Highland Ave, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, 600 Highland Ave, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, 600 Highland Ave, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA
[5] Kendrick Labs, Madison, WI USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; PROTEASOME-MEDIATED PROTEOLYSIS; SMALL-ANIMAL PET; IN-VIVO; TARGET TISSUES; ESR1; MUTATIONS; F-18-FLUOROESTRADIOL; THERAPY; RESPONSIVENESS; FEASIBILITY;
D O I
10.1148/radiol.2017162956
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the binding specificity of F-18-16 alpha-17 beta-fluoroestradiol (FES) in estrogen receptor (ER) alpha-positive breast cancer cells and tumor xenografts. Materials and Methods: Protocols were approved by the office of biologic safety and institutional animal care and use committee. By using ER-negative MDA-MB-231 breast cancer cells, clonal lines were created that expressed either wild-type (WT; 231 WT ER) or G521R mutant ER alpha (231 G521R ER), which is defective in estradiol binding. ERa protein levels, subcellular localization, and transcriptional function were confirmed. FES binding was measured by using an in vitro cell uptake assay. In vivo FES uptake was measured in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imaging of 24 mice (17 WT ER tumors, nine mutant G521R ER tumors, eight MDA-MB-231 tumors, and four MCF-7 ER-positive tumors). Statistical significance was determined by using Mann-Whitney (Wilcoxon rank sum) test. Results: ERa transcriptional function was abolished in the mutated 231 G521R ER cells despite appropriate receptor protein expression and nuclear localization. In vitro FES binding in the 231 G521R ER cells was reduced to that observed in the parental cells. Similarly, there was no significant FES uptake in the 231 G521R ER xenografts (percent injected dose [ ID] per gram, 0.49 +/- 0.042), which was similar to the negative control MDA-MB-231 xenografts (percent ID per gram, 0.42 +/- 0.051; P =.20) and nonspecific muscle uptake (percent ID per gram, 0.41 +/- 0.0095; P =.06). Conclusion: This study showed that FES retention in ER-positive breast cancer is strictly dependent on an intact receptor ligand-binding pocket and that FES binds to ERa with high specificity. These results support the utility of FES imaging for assessing tumor heterogeneity by localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality. (C) RSNA, 2017
引用
收藏
页码:868 / 876
页数:9
相关论文
共 50 条
  • [41] Fluoroestradiol F18 positron emission tomography diagnostic performance to characterize estrogen receptor status in breast cancer
    Webner, Peter
    Kurland, Brenda F.
    Wiggins, Jay R.
    Coche, Amandine
    Fontan, Charlotte
    Bouvet, Yann
    Divgi, Chaitanya
    Linden, Hannah M.
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16?-18F-Fluoro-17?-Fluoroestradiol
    Ulaner, Gary A.
    Mankoff, David A.
    Clark, Amy S.
    Fowler, Amy M.
    Linden, Hannah M.
    Peterson, Lanell M.
    Dehdashti, Farrokh
    Kurland, Brenda F.
    Mortimer, Joanne
    Mouabbi, Jason
    Moon, Dae Hyuk
    de Vries, Elisabeth G. E.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (03) : 351 - 354
  • [43] Two Cases of Diffuse Mild-Moderate 18F-Fluoroestradiol Lung Uptake in Women with Metastatic Estrogen Receptor Positive Breast Cancer
    Phillips, E.
    Karak, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S252 - S252
  • [44] Factors affecting the level and heterogeneity of uptake of [18F]fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer.
    Mankoff, DA
    Peterson, LM
    Petra, PH
    Stekhova, SA
    Link, JM
    Gralow, JR
    Livingston, RB
    Schubert, EK
    Tewson, TJ
    Krohn, KA
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 286P - 286P
  • [45] New approach to production and quality control of 16α-[18F] fluoroestradiol ([18F] FES: The effective functional molecular imaging probe for positive estrogen receptors breast cancer
    Dadashov, Z.
    Shukurov, R.
    Valiyev, M.
    Eryilmaz, K.
    Balashov, M.
    Novruzov, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S743 - S743
  • [46] ESTROGEN RECEPTOR-BINDING RADIOPHARMACEUTICALS FOR THE IMAGING OF ESTROGEN RECEPTOR-POSITIVE HUMAN BREAST-TUMORS
    RIJKS, LJM
    DEBRUIN, K
    VANROYEN, EA
    BOER, GJ
    ENDERT, E
    JANSSEN, AGM
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (05) : P225 - P225
  • [47] Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer
    Goldberg, Jonathan
    Qiao, Na
    Guerriero, Jennifer L.
    Gross, Brett
    Meneksedag, Yagiz
    Lu, Yoshimi F.
    Philips, Anne V.
    Rahman, Tasnim
    Meric-Bernstam, Funda
    Roszik, Jason
    Chen, Ken
    Jeselsohn, Rinath
    Tolaney, Sara M.
    Peoples, George E.
    Alatrash, Gheath
    Mittendorf, Elizabeth A.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 496 - 504
  • [48] Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
    Datta, Jharna
    Willingham, Natalie
    Manouchehri, Jasmine M.
    Schnell, Patrick
    Sheth, Mirisha
    David, Joel J.
    Kassem, Mahmoud
    Wilson, Tyler A.
    Radomska, Hanna S.
    Coss, Christopher C.
    Bennett, Chad E.
    Ganju, Ramesh K.
    Sardesai, Sagar D.
    Lustberg, Maryam
    Ramaswamy, Bhuvaneswari
    Stover, Daniel G.
    Cherian, Mathew A.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Characterization of estrogen receptor-negative/progesterone receptor-positive breast cancer
    Shen, Tiansheng
    Brandwein-Gensler, Margaret
    Hameed, Omar
    Siegal, Gene P.
    Wei, Shi
    HUMAN PATHOLOGY, 2015, 46 (11) : 1776 - 1784
  • [50] The Predictive Value of Early Changes in 18F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
    He, Min
    Liu, Cheng
    Shi, Qin
    Sun, Yuyun
    Zhang, Yongping
    Xu, Xiaoping
    Yuan, Huiyu
    Zhang, Yingjian
    Liu, Yin
    Liu, Guangyu
    Di, Genhong
    Yang, Zhongyi
    Wang, Zhonghua
    Shao, Zhiming
    ONCOLOGIST, 2020, 25 (11): : 927 - 936